The US Food and Drug Administration has approved a lower dose of Regeneron’s coronavirus treatment for injection, reports Axios.
The update to the company's emergency use authorisation, which was first issued in November, will make it easier for doctors to administer the treatment to coronavirus patients, since they can now do so by simple injection rather than intravenous infusion. Some health officials have said Regeneron’s monoclonal antibodies drug has been underused partly because not all clinics and hospitals are equipped to administer intravenous infusions, according to the Wall Street Journal.
Full Axios report (Open access)
See also from the MedicalBrief archives:
Regeneron antibody cocktail cuts COVID-19 hospitalisation and deaths
Injected antibody cocktail cuts COVID-19 infection risk by over 80%